FDA Approves Neurotech’s ENCELTO for Treatment of Macular Telangiectasia Type 2
ENCELTO becomes the first and only FDA-approved therapy for macular telangiectasia type 2. Neurotech Pharmaceuticals (Rhode Island, United States) announced…
AAO 2024 Subspecialty Day Update: Neovascular AMD
Some of the top names in retina, from Dr. Judy Kim (USA) to Prof. Gemmy Cheung (Singapore), gave updates on…
popular posts
latest posts